These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 7577479)

  • 41. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
    Arpino G; Green SJ; Allred DC; Lew D; Martino S; Osborne CK; Elledge RM
    Clin Cancer Res; 2004 Sep; 10(17):5670-6. PubMed ID: 15355892
    [TBL] [Abstract][Full Text] [Related]  

  • 42. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.
    Berns EM; Klijn JG; van Putten WL; de Witte HH; Look MP; Meijer-van Gelder ME; Willman K; Portengen H; Benraad TJ; Foekens JA
    J Clin Oncol; 1998 Jan; 16(1):121-7. PubMed ID: 9440732
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin.
    Pavlidis N; Briassoulis E; Bai M; Fountzilas G; Agnantis N
    Anticancer Res; 1995; 15(6B):2563-7. PubMed ID: 8669824
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients.
    Morgan LR
    Semin Oncol; 1985 Mar; 12(1 Suppl 1):43-7. PubMed ID: 3975652
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy.
    Robertson JF; Williams MR; Todd J; Nicholson RI; Morgan DA; Blamey RW
    Eur J Cancer Clin Oncol; 1989 Mar; 25(3):469-75. PubMed ID: 2703001
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preliminary study on oncogene product immunohistochemistry (c-erbB-2, c-myc, ras p21, EGFR) in breast pathology.
    Saccani Jotti G; Fontanesi M; Bombardieri E; Gabrielli M; Veronesi P; Bianchi M; Becchi G; Bogni A; Tardini A
    Int J Biol Markers; 1992; 7(1):35-42. PubMed ID: 1349907
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transforming growth factor-alpha and endocrine sensitivity in breast cancer.
    Nicholson RI; McClelland RA; Gee JM; Manning DL; Cannon P; Robertson JF; Ellis IO; Blamey RW
    Cancer Res; 1994 Apr; 54(7):1684-9. PubMed ID: 8137282
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients.
    Pérez-Tenorio G; Stål O;
    Br J Cancer; 2002 Feb; 86(4):540-5. PubMed ID: 11870534
    [TBL] [Abstract][Full Text] [Related]  

  • 51. p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival.
    Barbareschi M; Caffo O; Doglioni C; Fina P; Marchetti A; Buttitta F; Leek R; Morelli L; Leonardi E; Bevilacqua G; Dalla Palma P; Harris AL
    Br J Cancer; 1996 Jul; 74(2):208-15. PubMed ID: 8688323
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
    J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
    Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
    Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival.
    Pich A; Margaria E; Chiusa L
    J Clin Oncol; 2000 Aug; 18(16):2948-56. PubMed ID: 10944127
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of four oestrogen-responsive genes, pLIV1, pS2, pSYD3 and pSYD8, in predicting responsiveness to endocrine therapy in primary breast cancer.
    Manning DL; McClelland RA; Gee JM; Chan CM; Green CD; Blamey RW; Nicholson RI
    Eur J Cancer; 1993; 29A(10):1462-8. PubMed ID: 8398276
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumour markers predictive of successful treatment of breast cancer with primary endocrine therapy in patients over 70 years old: a prospective study.
    Stotter A; Walker R
    Crit Rev Oncol Hematol; 2010 Sep; 75(3):249-56. PubMed ID: 19969469
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients.
    Knoop AS; Bentzen SM; Nielsen MM; Rasmussen BB; Rose C
    J Clin Oncol; 2001 Jul; 19(14):3376-84. PubMed ID: 11454885
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.